Medigus endoscopy platform for GERD eyes worldwide clinical adoption
Minimally invasive endoscopy device maker Medigus is working to launch its MUSE endoscopy platform commercially worldwide, which treats gastroesophageal reflux disease (GERD) without the need for incision.
Minimally invasive endoscopy device maker Medigus (Omer, Israel) is working to launch its MUSE endoscopy platform commercially worldwide, which treats gastroesophageal reflux disease (GERD) without the need for incision.
The platform features a single-use surgical endostapler equipped with the company's miniature camera, an ultrasonic sight, and a rangefinder to perform surgical anterior fundoplication in a less invasive way compared to other methods. The approach uses standard surgical staples with clinical data comparable to current surgical procedures. What's more, it is an outpatient procedure that could potentially eliminate lifelong medication, in addition to less hospital readmissions and hospitalizations and reduced costs to the healthcare system.
In addition to the nearly 100,000 laparoscopic anti-reflux procedures performed in the U.S., the potential for the MUSE platform in the U.S., which comprises about 20 percent of the global market, is roughly 24 million GERD patients.
The company will continue to provide ongoing commercial and clinical validation regarding the platform's safety, efficacy, and cost value, supported by upcoming data and expected journal publications including abstracts at the 2014 Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) and Digestive Disease Week (DDW) medical meetings, explains CEO Chris Rowland.
Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn
Subscribe now to BioOptics World magazine; it's free!